HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3)

Vincenzo Arena, Marco Racioppi, Pierfrancesco Bassi, Francesco Pierconti, Luca Bongiovanni, Fabio Maria Vecchio

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To evaluate if the Human epidermal growth factor receptor 2 (HER-2) expression levels may be used as potential prognostic marker in high grade T1 blad- der cancer (T1G3) METHODS: Specimens from transurethral resection of bladder tumour (TURBT) of 103 patients with high-grade T1 bladder cancer were collected. This pathologic database was reviewed. Four-year follow-up data were matched with pathologic data. Eighty-three patients entered the study. HER-2 staining was performed. Patients were grouped for HER-2 status. Statistical analysis included Kaplan Meier survival analysis and Log-rank test.
Original languageEnglish
Pages (from-to)73-77
Number of pages5
JournalArchivio Italiano di Urologia Andrologia
Volume85
DOIs
Publication statusPublished - 2013

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Transitional Cell
  • Cystectomy
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Proteins
  • Neoplasm Staging
  • Prognosis
  • Receptor, ErbB-2
  • Tumor Markers, Biological
  • Urinary Bladder Neoplasms

Fingerprint

Dive into the research topics of 'HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3)'. Together they form a unique fingerprint.

Cite this